| Abstract O31 – Table 1. Characteristics of 441 included participants in the AGEhIV COVID‐19 substudy (at the time of 4 to 13 weeks after last dose of a COVID‐19 vaccine), by HIV‐status. All values are n (%) or median (interquartile range). A) Last available data prior to receiving last vaccine dose of the primary vaccination course. B) HIV‐1 viral load missing in 1/195 PWHIV. | |||
|---|---|---|---|
| People with HIV (n = 195) | Controls (n = 246) | p | |
| Age, yr | 63.3 (58.7 to 68.3) | 61.6 (58.0 to 67.5) | 0.145a |
| Male sex at birth | 184 (94.4%) | 211 (85.8%) | 0.003b |
| Ethnic origin ‐ Caucasian ‐ African ‐ Asian | ‐ 190 (97.4%) ‐ 5 (2.6%) ‐ 0 (0.0%) | ‐ 237 (96.4%) ‐ 4 (1.6%) ‐ 5 (2.0%) | 0.109c |
| BMI, kg/m2 (A) ‐ Underweight (<18.5) ‐ Normal weight (18.5 to 24.9) ‐ Overweight (25.0 to 29.9) ‐ Obese (30.0) | ‐ 1 (0.5%) ‐ 101 (51.8%) ‐ 72 (36.9%) ‐ 21 (10.8%) | ‐ 0 (0.0%) ‐ 118 (48.0%) ‐ 97 (39.4%) ‐ 31 (12.6%) | 0.608c |
| Total comorbidities (A) ‐ 0 comorbidities ‐ 1 to 2 comorbidities ‐ 3 to 7 comorbidities | ‐ 79 (40.5%) ‐ 96 (49.2%) ‐ 20 (10.3%) | ‐ 154 (62.6%) ‐ 78 (31.7%) ‐ 14 (5.7%) | <0.001b |
| Current CD4 count, cells/mm3 (A) | 640 (500 to 850) | 810 (650 to 1010) | <0.001a |
| Current CD4 count (A) ‐ <350 cells/mm3 ‐ 350 to 499 cells/mm3 ‐ 500 to 749 cells/mm3 ‐ 750 cells/mm3 | ‐ 19 (9.8%) ‐ 26 (13.3%) ‐ 77 (39.5%) ‐ 73 (37.4%) | ‐ 3 (1.2%) ‐ 21 (8.5%) ‐ 72 (29.3%) ‐ 150 (61.0%) | <0.001c |
| Current CD8 count, cells/mm3 (A) | 750 (500 to 990) | 410 (300 to 560) | <0.001a |
| Current CD8 count (A) ‐ <350 cells/mm3 ‐ 350 to 499 cells/mm3 ‐ 500 to 749 cells/mm3 ‐ 750 cells/mm3 | ‐ 22 (11.3%) ‐ 24 (12.3%) ‐ 50 (25.6%) ‐ 99 (50.8%) | ‐ 88 (35.8%) ‐ 73 (29.6%) ‐ 42 (17.1%) ‐ 43 (17.5%) | <0.001c |
| Current CD4/8 ratio (A) | 0.86 (0.65 to 1.22) | 1.87 (1.32 to 2.56) | <0.001a |
| Current CD4/8 ratio (A) ‐ <0.50 ‐ 0.50 to 0.99 ‐ 1.0 | ‐ 21 (10.8%) ‐ 98 (50.2%) ‐ 76 (39.0%) | ‐ 0 (0.0%) ‐ 21 (8.5%) ‐ 225 (91.5%) | <0.001c |
| Time since HIV diagnosis, yr | 22.6 (17.1 to 27.9) | NA | … |
| Time since first starting ART, yr | 19.8 (13.9 to 24.7) | NA | … |
| CD4 nadir, cells/mm3 | 180 (70 to 260) | NA | … |
| Undetectable HIV‐1 viral load (A, B) | 193 (99.5%) | NA | … |
| COVID‐19 vaccine type ‐ BNT162b2 ‐ mRNA‐1273 ‐ ChAdOx1 ‐ Ad26.COV2.S ‐ ChAdOx1+BNT162b2 | ‐ 122 (62.6%) ‐ 8 (4.1%) ‐ 61 (31.3%) ‐ 3 (1.5%) ‐ 1 (0.5%) | ‐ 167 (67.9%) ‐ 6 (2.4%) ‐ 64 (26.0%) ‐ 6 (2.4%) ‐ 3 (1.2%) | 0.491c |
| Only one dose of BNT162b2, mRNA‐1273 or ChAdOx1 due to prior SARS‐CoV‐2 infection | 2 (1.0%) | 8 (3.3%) | 0.284c |
| Days between pre‐vaccination sample and first vaccine dose | 44 (26 to 67) | 45 (28 to 74) | 0.702a |
| Days between first and second vaccine dose ‐ BNT162b2 ‐ mRNA‐1273 ‐ ChAdOx1 ‐ ChAdOx1 + BNT162b2 | ‐ 35 (35 to 36) ‐ 28 (28 to 32) ‐ 77 (63 to 77) ‐ 88 (88 to 88) | ‐ 36 (35 to 36) ‐ 32 (28 to 36) ‐ 76 (68 to 77) ‐ 65 (33 to 113) | ‐ 0.096a ‐ 0.459a ‐ 0.538a ‐ 0.655a |
| Days between last vaccine dose and post‐vaccination sample | 64 (46 to 76) | 70 (43 to 77) | 0.262a |
| Prior SARS‐CoV‐2 infection ‐ prior to pre‐vaccination sample ‐ between pre‐ and post‐vaccination sample | ‐ 20 (10.3%) ‐ 8 (4.1%) | ‐ 25 (10.2%) ‐ 9 (3.7%) | 0.877b |
BMI, body mass index; NA, not applicable; yr, in years.
aWilcoxon rank‐sum test;
bPearson χ2 test;
cFisher's exact test.